A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin
NCT01624025
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
22
Enrollment
OTHER
Sponsor class
Conditions
Metastatic Advanced Gastric Cancer
Interventions
OTHER:
Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks
Sponsor
Yonsei University